Clinical Competition Candidate
QSYMIA
QSYMIA carries product and use-code patents, moderate complexity (3/5), and meaningful clinical competition (4/5). The listed expiry window is approximately 35 months away. Active clinical competition may compress the generic entry window.
LOE window
35months
to latest listed patent expiry (June 14, 2029)
Expiry attractiveness: 5/5
Patent profile
Substance patent (none)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 6
Complexity score: 3/5
Clinical competition
Score: 4/5
Active trials linked: 53
Phase 2/3 trials: 23
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: PHENTERMINE HYDROCHLORIDE; TOPIRAMATE
Applicant (NDA holder): VIVUS LLC
Confidence: High